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1. Introduction  
1.1. Classification of extracellular vesicles (EVs)  
Communications of cancer cells with each other or with 
neighboring cells or cells at distant sites are crucial for tumor 
proliferation and dissemination (Jakhar and Crasta 2019). 
Extracellular vesicles (EVs) are lipid bi-layered vesicles that are 
released from almost all cells under physiological and pathological 
conditions. EVs play a crucial role in intercellular communications at 
local and distant sites (Yáñez-Mó et al. 2015). These small vesicles 
carry various molecular cargo such as; nucleic acids (DNA, RNA), 
proteins, lipids, and metabolites that could be transferred into the 
recipient cells leading to genetic alterations and reprogramming of 
these cells (Raposo and Stoorvogel 2013; Colombo, Raposo, and 
Théry 2014; Yáñez-Mó et al. 2015; Eman A Taha, Ono, and Eguchi 
2019). 
According to the vesicle size, EVs are mainly classified into three 
categories; exosomes (50-200 nm), ectosomes are also known as 
microvesicles (MV) (100-500 nm), and apoptotic bodies (1-10 μm) 
(Andreola et al. 2002; Janowska-Wieczorek et al. 2005; Lawson et al. 
2016). In addition to this heterogenous population, other vesicles have 
been reported including., oncosomes (Al-Nedawi et al. 2008; Rak 
2013; Choi et al. 2019), large oncosomes (1-10 μm) (Di Vizio et al. 
2012; Vagner et al. 2018), matrix vesicles (Mebarek et al. 2013; Chen 
et al. 2016; Schmidt et al. 2016), migrasomes (50 nm to 3 μm) (Ma et 
al. 2015; Huang et al. 2019), exopheres (~4 μm), exomeres (~35 nm), 
and bacterial outer membrane vesicles (OMV) (Raposo and 
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Stoorvogel 2013; Kim et al. 2017; Van Niel, D’Angelo, and Raposo 
2018; Coelho et al. 2019).  
Notably, EVs are heterogeneous populations, so there is no 
unanimous consensus on the nomenclature of them. General terms 
such as “exosomes” and “microvesicles” have been broadly used. The 
International Society for Extracellular Vesicles (ISEV) proposed to 
use the term EVs in general to describe vesicles naturally released 
from the cells and surrounded by a lipid bilayer unless authors can 
establish specific markers of subcellular origin with a description 
based of physical characteristics, such as size (Théry et al. 2018). 
Thus, I will use the general term EVs, and classify it into small and 
large EVs based on the size of vesicles.  
1.2. Biogenesis and characteristics of EVs 
Exosomes are vesicles of endosomal origin. Their biogenesis 
starts with the inward budding of the cellular plasma membrane, 
internalization of extracellular ligands from the cell surface (e.g., 
growth factor receptors) or from the Golgi apparatus (e.g., MHC 
class-II molecules) forming early endosomes (Babst 2005; Trajkovic 
et al. 2008; Fader and Colombo 2009; Babst 2011; Colombo et al. 
2013; Jakhar and Crasta 2019; Eman A Taha, Ono, and Eguchi 2019). 
Early endosomes mature into late endosomes. After that, the 
endosomal membrane undergoes a second inward (intraluminal) 
budding to generate smaller vesicles within the late endosome lumen 
to form multivesicular bodies (MVBs), which are carrying various 
bioactive molecules such as proteins, lipids, and nucleic acids of the 
parent cell. Finally, MVBs either fuse with lysosomes to be degraded 
or fuse with the plasma membrane thereby releasing the intraluminal 
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vesicles, termed exosomes, into the extracellular space  (Figure 1 ) 
(Trajkovic et al. 2008; Fader and Colombo 2009; Babst 2011; 
Colombo et al. 2013; Jakhar and Crasta 2019; Eman A Taha, Ono, 
and Eguchi 2019). Once generated within the MVB, the release 
exosomes into the extracellular space are mediated by small transport 
GTPases molecules such as; Rab27A, Rab11, and Rab31, which can 
collaborate with SNARE (a soluble N-ethylmaleimide sensitive factor 
attachment protein receptor) proteins to fuse the MVB membrane 
with their target membrane (Bobrie et al. 2011). 
  
Figure 1. Schematic representation of exosome biogenesis and 
release (Jakhar and Crasta 2019).  
 
It is worth noting that the formation of exosomes within the 
MVBs occurs by the endosomal sorting complex required for 
transport (ESCRT)-dependent machinery and ESCRT-independent 
mechanisms. Four distinct ESCRT protein complexes have been 
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identified (ESCRT-0, -I, -II, and -III). The ESCRT-dependent 
biogenesis starts with the inward budding of the cell membrane with 
aid from ESCRT-0 to produce early endosomes. The other ESCRT 
complexes contributing to the packaging of exosome contents into 
late endosomes. Whereas, the ESCRT-independent biogenesis 
involves the packaging of proteins from the Golgi into exosomes 
within MVBs and discharged into the extracellular milieu in the 
absence of ESCRT machinery (Babst 2011; Jakhar and Crasta 2019).  
In general, EVs are characterized by their cup-shaped lipid 
bilayers structure under the electron microscope (Szatanek et al. 
2017). Despite the absence of specific protein markers to distinguish 
between the different subtypes of EVs, the protein profiles of MVs, 
exosomes, and apoptotic bodies are different due to their different 
routes of formation (F. T. Borges, Reis, and Schor 2013; Yáñez-Mó 
et al. 2015; Mikołaj P Zaborowski et al. 2015). For instance, the 
membrane of Exosome contains cholesterol, sphingomyelin, 
phosphatidylinositol, ceramide, and lipid rafts (Théry, Ostrowski, and 
Segura 2009; Ciardiello et al. 2016; Tamkovich, Tutanov, and 
Laktionov 2016).  
Besides, exosomes protein markers including tetraspanin family 
proteins (CD63, CD9, CD81, and CD82), members of ESCRT 
complex (TSG101, Alix), and heat shock proteins (HSP60, HSP70, 
HSPA5, CCT2, and HSP90) (Théry, Ostrowski, and Segura 2009; 
Simpson et al. 2009; Yoshioka et al. 2013; Fernanda T. Borges et al. 
2013; Yokoi, Yoshioka, and Ochiya 2015; Ciardiello et al. 2016; Ha, 
Yang, and Nadithe 2016). While, microvesicles membrane are 
enriched with cholesterol, diacylglycerol, and phosphatidylserine 
(Colombo, Raposo, and Théry 2014); and integrins, selectins, and 
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CD40 are the main protein markers for this category of EVs 
(Colombo, Raposo, and Théry 2014). 
 Furthermore, apoptotic bodies are distinguished from the other 
two major EV groups by the presence of fragmented DNA and cell 
organelles from their host cell (Mathivanan, Ji, and Simpson 2010; 
Akers et al. 2013; Boukouris and Mathivanan 2015). Moreover, 
apoptotic bodies have exposed phosphatidylserine on their 
membranes, and their major protein markers include histones, 
thrombospondin (TSP), and complement protein C3b (Théry et al. 
2001).  
1.3. EVs as modulators of the tumor microenvironment 
Tumor-derived EVs have been recently emerged as putative 
biological mediators in cancer (Rak and Guha 2012). EVs are highly 
specialized molecules in cellular communication, as they carry 
several oncogenic proteins, nucleic acids, and signaling molecules 
that can be transferred horizontally to the target cells and modulate 
the tumor microenvironment (TME) for supporting tumor growth, 
invasion, and metastasis (Higginbotham et al. 2011; Rak and Guha 
2012; Tovar-Camargo, Toden, and Goel 2016). The role of EVs in 
cancer progression and metastasis is described in detail below.  
The tumor microenvironment does not only consist of cancer 
cells but also a heterogeneous population of fibroblasts, endothelial 
cells, immune cells, cytokines, extracellular vesicles, and 
extracellular matrix, adipocytes, and vasculature (Balkwill, Capasso, 
and Hagemann 2012). The crosstalk between cancer cells and their 
surrounding environment plays a pivotal role in tumor development 
and progression (Balkwill, Capasso, and Hagemann 2012).  
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Cancer-associated fibroblasts (CAFs) are one of the most important 
members within the TME that represent the largest proportion of 
stroma cells by secreting extracellular matrix components (Xing, 
Saidou, and Watabe 2010). CAFs can promote the tumor invasion and 
metastasis, via the secretion of many cytokines such as vascular 
endothelial growth factor A (VEGFA), C-X-C motif chemokine 12 
(CXCL12), Interleukin 6 (IL-6), as well as remodeling of the 
extracellular matrix (ECM) (Alkasalias et al. 2018).  
It was reported that ovarian cancer-derived EVs are capable of 
modulating fibroblast's behavior towards a CAF-like state. The 
secretome of these CAFs stimulates the surrounding cells to promote 
the proliferation, motility, and invasion of the tumor and endothelial 
cells (Giusti et al. 2018). Moreover, it has been shown that 
transforming growth factor-beta  TGF-β1-associated EVs secreted 
from prostate cancer can trigger the differentiation of fibroblast into a 
myofibroblast phenotype resembling stromal cells isolated from 
cancerous prostate tissue; promoting in vitro angiogenesis and 
accelerating in vivo tumor growth (Webber et al. 2015). 
Abdouh et al. demonstrated that colorectal cancer (CRC) -
derived EVs were able to induce the transformation of fibroblasts into 
colon carcinoma cells in vitro (Abdouh et al. 2019). They showed that 
fibroblasts treated with CRC-derived EVs mediated the transfer of 
DNA that was actively transcribed in the fibroblasts after the EVs 
exposure (Abdouh et al. 2019).  
The groups also observed that a definite set of miRNA molecules 
was transferred from the CRC-derived EVs to the fibroblasts; 
activating cell cycle progression and cell survival pathways. 
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Furthermore, the injection of CRC-derived EVs in the tail vein of 
NOD-SCID mice prompted malignant transformation and metastases 
in the lungs of the mice (Abdouh et al. 2019).  
1.4. Fluorescent labeling of EVs 
Several methods have been developed to monitor the biogenesis, 
transmission, distribution, and subcellular localization of EVs, such 
as lipid-based fluorescence labelings (Yoshimura et al. 2016; Namba 
et al. 2018), such as the transmembrane protein CD63 fused with a 
green fluorescent protein (GFP) and red fluorescent protein (RFP) 
(CD63-GFP/RFP fusion) (Piao, Kim, and Moon 2019; Mikołaj Piotr 
Zaborowski et al. 2019), and membrane lipid-binding palmitoylation 
signal-fused fluorescent proteins such as tandem dimer Tomato 
(tdTomato) or enhanced green fluorescence protein (EGFP) as I 
abbreviate as palmGFP (palmG) and palmtdTomato (palmT) (Lai et 
al. 2015). 
 Protein S-acylation is a lipid modification that enables the 
covalent attachment of long-chain palmitic fatty acids to thiol groups 
of cysteine residues through a thioester linkage (Xu 2011; Verpelli et 
al. 2012). This type of protein modification is commonly known as S-
palmitoylation (S-PALM) allows the association of proteins with 
cellular membranes (Triola, Waldmann, and Hedberg 2012). The 
fusion of the fluorescent proteins with palmitoylation sequence to the 
cell membranes, enabling the whole-cell labeling (Zuber, Strittmatter, 
and Fishman 1989; Zacharias et al. 2002). As EVs are derived from 
the plasma membrane (Raposo and Stoorvogel 2013), I assumed that 
tagging the plasma membrane with fluorescent proteins would enable 
the labeling of multiple EVs types.  
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1.5. Structure of MMPs  
Metalloproteinases (MMPs) constitute a large family of zinc-
calcium dependent endopeptidases and they are considered as the 
main players in ECM remodeling (Berg, Barchuk, and Miksztowicz 
2019). Due to their ability to degrade numerous components of ECM, 
nucleus matrix, and non-ECM proteins, such as adhesion molecules, 
cytokines, protease inhibitors, and membrane receptors (Berg, 
Barchuk, and Miksztowicz 2019).  
MMPs play crucial roles in wound healing, angiogenesis, tissue 
remodeling, as well as in pathological processes, including wound 
healing (Nagaset and Woessner 1999; Ravanti and Kähäri 2000; Visse 
and Nagase 2003), inflammation (Y, H, and Jr 1987), and cancer 
(Coussens and Werb 1996; Curran and Murray 1999; Sternlicht and 
Werb 2001; Kessenbrock, Plaks, and Werb 2010). So far, the MMP 
family consists of about 28 members that share similarities in their 
structure, regulation, and function (Berg, Barchuk, and Miksztowicz 
2019).  
Based on structure and substrate specificity, MMPs can be further 
divided into six major subfamilies including collagenases, 
gelatinases, stromelysins, matrilysins, membrane-type MMPs, and 
other MMPs (Peng et al. 2012). All MMPs have three principal 
domains; (1) a pro-domain that functions as an intramolecular 
inhibitor to maintain the enzyme in an inactive state, (2) a catalytic 
domain that promotes the proteolytic activity, and (3) a hemopexin-
like repeat domain (PEX), which determines the substrate specificity 
(Figure 2) (Radisky and Radisky 2015).  
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Figure 2. The domain structure of MMPs. S, signal peptide; Pro, 
pro-peptide; CAT, catalytic domain; F, fibronectin type-II repeats; 
PEX, hemopexin domain; TM, transmembrane domain; GPI, 
glycophosphatidylinositol membrane anchor; C, cytoplasmic domain; 
CA, cysteine array; Ig, immunoglobulin-like domain. Adapted from 
(Radisky and Radisky 2015).  
 
The PEX domain is found in all MMPs except MMP-7 and 
MMP-26, thereby they are the smallest MMPs members that having 
only the pro-peptide and catalytic domains (Murphy et al. 1994; 
Steffensen, Wallon, and Overall 1995; Shipley et al. 1996; 
Mikhailova et al. 2012).  A more specialized domain including three 
fibronectin type II repeats, present in MMP-2 and MMP-9 and assist 
in recognizing elastin and denatured collagen as extracellular matrix 
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substrates (Murphy et al. 1994; Steffensen, Wallon, and Overall 1995; 
Shipley et al. 1996; Mikhailova et al. 2012).  
Additionally, while most MMPs are soluble extracellular 
proteins, MMPs-14, -15, -16, and -24 are type I membrane proteins 
that directly anchored through C-terminal transmembrane domains, 
MMP-17 and -25 is membrane localized via C-terminal 
glycophosphatidylinositol (GPI) anchors, and MMP-23 via an N-
terminal type II transmembrane domain (Rangaraju et al. 2010). 
Furthermore, MMP-23 possesses a unique cysteine array that 
modulates the ion channel activity and an adjacent immunoglobulin-
like domain, that similar to the PEX domain of other MMPs 
(Rangaraju et al. 2010).  This array mediates the protein-protein 
interactions involved in localization or substrate recognition 
(Rangaraju et al. 2010; Galea et al. 2014). 
1.6. Complex roles of MMPs in tumorigenesis 
The extracellular matrix serves as a niche for tumor cells to 
survive and proliferate. On the other hand, it acts as a barrier that 
suppresses the spreading of tumor cells. Degradation of ECM is one 
of the first steps in tumor invasion and metastasis (Lu et al. 2011; 
Venning, Wullkopf, and Erler 2015). ECM remodeling is tightly 
controlled to maintain tissue homeostasis, integrity, and functions. 
However, uncontrolled ECM dynamics causes deregulated cell 
proliferation, invasion, resistance to cell death, and can lead to the 
development of congenital defects and pathological diseases such as 
tissue fibrosis and cancer. Moreover, the ECM can act as a barrier 
against the immune cells or the anticancer drugs, e.g., blocking the 
penetration of immune cells into the tumor, or creating a high 
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interstitial fluid pressure (IFP) to prevent the drugs perfusion, thus 
facilitating cancer immune-escaping and chemoresistance (Lu et al. 
2011; Venning, Wullkopf, and Erler 2015).  
MMPs were found to promote cell invasion and motility by 
pericellular ECM degradation. For instance, the expression and 
activity MMP-2 and MMP-9 are strongly upregulated in human 
cancers and correlated with the tumor stage, metastasis, and poor 
prognosis (Lubbe et al. 2006). Besides, MT1-MMP, plays a crucial 
role in invasion and metastasis, by activating proMMP-2 and 
directing the cleavage of collagen types I, II, and III (Poincioux, 
Lizárraga, and Chavrier 2009). 
 Degradation of the ECM structures by MMPs not only breaks 
the barrier that prevents the metastatic spread of tumor cells but also 
produces bioactive molecules that foster tumor growth, proliferation, 
invasion, and metastasis. For example, cleavage of laminin-5 by 
MMP-2 and MT1-MMP generates epidermal growth factor EGF-like 
motifs containing fragments that trigger the epidermal growth factor 
receptor (EGFR) signaling and other larger fragments that engage the 
integrin signaling, thereby inducing the tumor cell migration 
(Koshikawa et al. 2005; Sadowski et al. 2005).  
Additionally, osteopontin cleavage by MMP-9 produces a 5-kDa 
fragment that facilitates tumor cell invasion (Takafuji et al. 2007). 
What is more, MMP-7 and MMP-9 have been shown to cleave 
insulin-like growth factor-binding protein (IGFBP), as a result, 
enhancing the insulin-like growth factor (IGF) bioavailability and 
activation of insulin-like growth factor receptor (IGFR) signaling 
(Mañes et al. 1999; 1997; Rorive et al. 2008). 
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Another study has reported that MT1-MMP cleaves heparin-
binding EGF-like growth factor (HB-EGF) and removes the 20 amino 
acids from the amino (NH2)-terminal region, that are necessary for 
heparin-binding. The truncated HB-EGF form was found to stimulate 
the EGFR/ERBB signaling (Rorive et al. 2008; Koshikawa et al. 
2010). Moreover, MT1-MMP degrades the protein-tyrosine kinase-7 
(PTK7), an inhibitor of cell invasion, thus stimulating cell invasion 
and migration (Golubkov et al. 2010).  
MMPs are capable of modulating cancer progression by 
promoting invasion, metastasis, and angiogenesis. Both tumor cells 
and neighboring stromal cells can secret MMPs which degrade the 
physical barriers and facilitate cancer cells angiogenesis as well as 
invasion and metastasis (Gialeli, Theocharis, and Karamanos 2011).  
Furthermore, MMPs support tumor growth and angiogenesis via 
increasing the availability of signaling molecules, such as growth 
factors and cytokines, by liberating them from the ECM (IGF, bFGF, 
and VEGF) or by increasing their shedding by from the cell surface 
(EGF, TGF‐α, HB‐EGF). Besides, MMPs induce angiogenic switch 
through the downregulation of angiogenic inhibitors and upregulation 
of angiogenic stimulators factors. Moreover, MMPs can modulate the 
cell-cell interactions and provoke the ECM through the processing of 
E‐cadherin and integrins, respectively, thereby, increasing cell 
migration (Figure 3) (Gialeli, Theocharis, and Karamanos 2011). 
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Figure 3. The Pivotal role of MMPs in cancer progression (Gialeli, 
Theocharis, and Karamanos 2011).  
 
1.7. MMPs in EVs  
Several studies have reported that several MMP family members 
were packaged in EVs from body fluids or various types of cell lines 
(Dolo et al. 1999; Taraboletti et al. 2002; Belhocine et al. 2010; 
Shimoda and Khokha 2013; Reiner et al. 2017; Okusha et al. 2020). 
For instance, prostate cancer-derived oncosomes were shown to 
contain bioactive MMP2, MMP9 molecules that are involved in local 
invasion, and correlated with tumor progression (Di Vizio et al. 2012). 
Another study revealed that vesicles shed from the cultured human 
umbilical vein endothelial cells are containing active 
and proenzyme forms of gelatinases, MMP-2 and MMP-9 as well as 
the MT1-MMP proenzyme that was located on the external side of 
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the vesicle membrane, all these proteases initiated the proteolysis 
necessary for tumor invasion and angiogenesis (Taraboletti et al. 
2002). Furthermore, MMP13-containing exosomes were found to 
facilitate the metastasis of nasopharyngeal cancer cells (an endemic 
type of head and neck cancer associated with a high rate of cervical 
lymph node metastasis) through the induction of EMT (You et al. 
2015).   
Also Hendrix et al. reported that Rab27b-mediated exocytic 
release of HSP90 exosomes from metastatic breast cancer cells can 
activate MMP2 resulting in the degradation of ECM components and 
release of growth factors, promotion of cancer cell invasion (Hendrix 
et al. 2010). Additionally, San-chez et al. have recently demonstrated 
that prostate cancer stem cells secreted exosomes that are enriched 
with miRNAs such as miR-100-5p, miR21-5p, and miR-139-5p. 
These exosomal miRNA increased the expression of MMP2, MMP9, 
MMP13, and RANKL, also enhanced the fibroblasts migration, 
thereby contributing to local invasion and pre-metastatic niche 
formation (Sánchez et al. 2016). 
Moreover, Hiratsuka et al. have shown that MMP9 induced by 
primary tumors in lung endothelial cells and macrophages 
significantly promoted the lung metastasis, the induction of MMP9 
was dependent on the tyrosine kinase VEGFR-1 (Hiratsuka et al. 
2002). Blocking of the MMP9 induction via deletion of either 
VEGFR-1TK or MMP9 markedly diminished the lung metastasis in 
mice models (Hiratsuka et al. 2002).  
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1.8. The two-dimensional and three- dimensional culture 
systems 
The two-dimensional (2D) cell culture system has been 
frequently used for cancer research and drug screening (Yoshii et al. 
2011). In conventional 2D culture systems, cells are cultured as 
monolayers on flat surfaces of plates which allow each cell to access 
the same amount of growth factors and nutrients present in the 
medium, resulting in homogenous growth and proliferation 
(Edmondson et al. 2014). Besides, the strong physical interaction 
present between cells and 2D culture substrates resulted in alteration 
in the tumor cell behaviors that differ from those of tumors growing 
in vivo (Yoshii et al. 2011). Thus, the 2D culture model fails to 
correctly mimic the proper tissue architecture and complex 
microenvironment in vivo (Lv et al. 2017).  
To overcome the limitations of the 2D culture system, a three-
dimensional (3D) cell culture model (aka a spheroid or organoid 
culture) have been developed to better mimic in vivo tissue 
microenvironments (Lv et al. 2017; Duval et al. 2017). The 3D culture 
model maintains the interactions between cells and their ECM, create 
gradient access of oxygen and nutrient, and buildup a combination of 
tissue-specific scaffolding cells (Griffith and Swartz 2006).  
Similar to human cancers, proliferating, quiescent, and dying 
cells are coexisting in normoxic, hypoxic, or necrotic zones within 
tumor organoids (Hirschhaeuser et al. 2010; Eguchi et al. 2018; 
Namba et al. 2018). Thus, the 3D tumor models reflect more closely 
the in vivo human tumors, which prompted us to define tumor 
organoids as “tumoroids”. Among several methodologies of tumoroid 
models, we have adopted gel-free tumoroid models cultured on 
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NanoCulture Plates (NCP) and ultra-low attachment (ULA) plates 
(Arai et al. 2016; Eguchi et al. 2018; Namba et al. 2018; Sogawa et 
al. 2019; 2020).  
A great advantage of the gel-free tumoroid model is the 
collectability of the secretome including EVs from their culture 
supernatants. NCP is a nanopatterned gel-free scaffold for 3D cell 
culture (Elsayed and Merkel 2014). The mogul field structure on 
NCPs restricts cells to sprawl on the base and enable tumor cells to 
migrate from a scaffold to another scaffold more actively than cells 
cultured on the 2D plate.  
The increased migration and lesser attachment of cancer cells on 
the NCPs enable tumor cells to form 3D tumoroids (Arai et al. 2016; 
Eguchi et al. 2018; Namba et al. 2018; Sogawa et al. 2019; 2020). 
ULA plates have been also useful for the collection of secretome 
including EVs. Cells do not rapidly migrate on ULA plates compared 
to NCPs. We have examined a few types of culture media such as 
serum-containing media versus serum-free stemness-enhancing 
media in combination with the 3D culture systems. In vitro culture of 
tumoroids in such a 3D nano-environment combined with a defined 
stem cell medium enabled the cells to grow slowly and form large 
organoids that expressed multiple stem cell markers and intercellular 
adhesion molecules (Eguchi et al. 2018; Namba et al. 2018). 
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2. Aim and objective 
Here, I explored (i) the tumorigenic role of MMP3 on the in vitro 
tumoroid formation under the 3D culture system and on their EVs 
integrity, (ii) whether MMP3-rich or MMP3-null EVs could alter 
tumoroid formation, and examined (iii) the EVs-mediated molecular 
transfer of MMP3 into the MMP3-KO tumoroids under the 3D culture 
system. 
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3. Materials and methods 
3.1. Cells 
A rapidly metastatic murine cancer cell line LuM1 (Sakata et al. 
1996; Namba et al. 2018; Sogawa et al. 2020) and MMP3-KO cells 
line (Okusha et al. 2020) were maintained in RPMI-1640 with 10% 
fetal bovine serum (FBS) and penicillin, streptomycin, and 
amphotericin B. MMP3-KO cells were established using the 
CRISPR/Cas9 system from the LuM1 cell line (Okusha et al. 2020). 
Briefly, Cas9 protein and guide RNA that targets Mmp3 exon 1 were 
co-transfected into LuM1 and stable MMP3-KO clones with frame-
shifting deletion were obtained.  
3.2. Tumoroid culture 
Tumoroids were formed in the 3D culture systems using 
NanoCulture Plate (NCP) (Medical & Biological Laboratories, 
Nagoya, Japan) or ultra-low attachment (ULA) culture plates/dishes 
(Greiner, Kremsmunster, Austria) within mTeSR1 stem-cell medium 
(Stemcell Technologies, Vancouver, Canada) or the above-mentioned 
serum-containing medium as described previously (Eguchi et al. 
2018; Namba et al. 2018; Sogawa et al. 2019; 2020).  
For quantification of tumoroids size and number, cells were 
seeded in a 96 well NCP for 14 days at a concentration of 5.0 x 103 
cells in 200 μL mTeSR1 or RPMI-1640 media with 10% FBS. 
Tumoroid maturation was monitored every day and photographed 
using the Floid cell imaging station (Thermo Fisher, Waltham, MA, 
USA) from day 1 until day 7 and a BZ-X microscope (Keyence, 
Osaka, Japan) starting from day 10 until the end of the experiment 
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day 14. The tumoroid size was measured using Image J software 
(NIH, Bethesda, MD, USA).  
3.3. 2D re-seeding assay 
Tumoroids were cultured in the 3D and stem-cell medium 
condition for 14 days and detached by trypsin/EDTA. The detached 
cells were re-seeded in a 24-well 2D culture plate at a concentration 
of 1.5 × 104 cells/well in RPMI-1640 with 10% FBS. The cell images 
were taken by using the Floid cell imaging station (Thermo Fisher, 
Waltham, MA, USA) on days 2, 4, 6, and 7 after the seeding.  
3.4. Preparation of EVs and conditioned media 
Tumoroid-derived EVs were used for tumoroid formation assays. 
Otherwise, 2D cultured cells-derived CM was used for 2D 
experiments. EVs were prepared from culture supernatants of 
tumoroids using a modified polymer-based precipitation method 
(Fujiwara et al. 2018; Ono et al. 2018; Eguchi et al. 2020). Briefly, 
cells were seeded on a 10-cm ULA dish at a density of 1.0 × 106 
cells/8 mL mTeSR1 medium and cultured for 6 days. The formed 
tumoroids were washed with PBS (-), and then further cultured in 
serum-free medium (4 mL per dish) for 2 days. Cell culture 
supernatant was collected and centrifuged at 2,000 × g for 30 min at 
4°C to remove detached cells. The supernatant was then centrifuged 
at 10,000 × g for 30 min at 4°C to remove cell debris. The supernatant 
(8 mL) was concentrated to less than 1 mL by using an Amicon Ultra-
15 Centrifugal Filter Devices for M.W. 100k (Merck Millipore, 
Burlington, MA). The concentrate was applied to the Total EVs 
Isolation System (Thermo Fisher, Waltham, MA, USA). The pass-
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through was concentrated using an ultrafiltration device for molecular 
weight 10 kD and used as a non-EV fraction. The EV fraction was 
suspended in 100 µL PBS (-) and used 3D-tumoroid-EVs. Protein 
concentration was measured using a micro BCA protein assay kit 
(Thermo Fisher, Waltham, MA, USA).  
For immunofluorescence in the 2D culture system, culture 
supernatants were collected from serum-free media of 2D-cultured 
donor cells during the exponential growth phase (70% confluence). 
The culture supernatants were centrifuged at 2,000 x g for 15 min to 
get rid of cells and debris, followed by diluting in a ratio 1:1 with a 
fresh culture medium. The CM was stored at -80°C. Recipient cells 
were treated with the CM for 48 h.  
3.5. Transmission electron microscopy 
As described previously (Eguchi et al. 2018; 2020), a 400-mesh 
copper grid coated with formvar/carbon films was hydrophilically 
treated. The EVs suspension (5-10 µL) was placed on Parafilm, and 
the grid was visualized at 5,000, 10,000, or 20,000 times 
magnification with an H-7650 transmission electron microscope 
(TEM) (Hitachi, Tokyo, Japan) at the Central Research Laboratory, 
Okayama University Medical School.  
3.6. Particle diameter distribution 
As described previously (Fujiwara et al. 2018; Eguchi et al. 2020), 40 
µL of EV fraction within PBS (-) was used. Particle diameters of the 
EV fractions in a range between 0 and 6,000 nano-diameters were 
analyzed in Zetasizer nano ZSP (Malvern Panalytical, Malvern, UK). 
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3.7. Western blotting 
Western blotting was performed as described (Ono et al. 2018; 
Eguchi et al. 2020). Cells were cultured for 6 days on a 6 well ULA 
plate at a density of 3.0 x 105 cells/3 mL mTeSR1 medium in a well. 
Cells were further cultured in serum-free media for 2 days. On day 8, 
the supernatants and tumoroids were collected, centrifuged at 2000 x 
g, 4˚C for 5 min. The supernatants were used for EV preparations as 
mentioned above.  
To prepare whole cell lysate (WCL), tumoroids were lysed in a 
RIPA buffer (1% NP-40, 0.1% SDS, and 0.5% deoxycholate, and 
EDTA-free protease inhibitor cocktail in PBS) using 25-gauge 
syringes. The cell lysate was incubated for 30 min on ice and then 
centrifuged at 12,000 g for 20 min at 4˚C. The preparation method of 
EV and non-EV fraction was described above. The supernatant was 
used as WCL. The same protein amounts for each lane were subjected 
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), followed by transfer to a polyvinylidene fluoride (PVDF) 
membrane using a semi-dry transfer system.  
The membranes were blocked in 5% skim milk in Tris-buffered 
saline containing 0.05% Tween 20 for 60 min at room temperature 
(RT) and then incubated overnight with rabbit monoclonal antibodies; 
anti-MMP3 (EP1186Y, ab52915, Abcam, Cambridge, UK) or anti-
CD9 (EPR2949, ab92726, Abcam, Cambridge, UK) or anti-CD63 
(EXOAB-CD63A-1, System Biosciences). For CD63, blocking was 
performed in 10% overnight and the primary antibody was reacted for 
2 days. The membranes were incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibodies. For GAPDH, the HRP-
conjugated anti-GAPDH mouse monoclonal antibody (HRP-60004, 
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Proteintech, Rosemont, IL, USA) was used. For Actin, anti-Actin 
rabbit antibody (A2066, Sigma Aldrich, St. Louis, MO, USA) was 
utilized. Blots were visualized with the ECL substrate (Merck 
Millipore, Burlington, MA, USA). 
3.8. Coomassie blue staining (CBS) 
Protein samples (1 µg each) were loaded on the SDS-PAGE. 
After the electrophoresis run, the gel was stained with Coomassie 
Brilliant Blue R-250 solution (1610436, Bio-Rad, Hercules, CA, 
USA) for 30 min with gentle agitation followed by washing with the 
destaining solution (50% methanol, 10% glacial acetic acid) for 2 h 
until the background became less dark. 
3.9. EV-driven in vitro tumorigenesis  
MMP3-KO cells were seeded at 5.0 x 103 cells/200 μL mTeSR1 
medium in a well of 96-well NCP. After two days, EVs derived from 
3D-tumoroids (LuM1 or MMP3-KO) were added to MMP3-null 
tumoroids at a final concentration of 5 μg/mL. Then the plate was 
centrifuged at 1,800 × g for 1 h at 4˚C to increase the internalization 
of EVs into the tumoroids (Lai et al. 2015). The MMP3-KO tumoroids 
maturation was monitored over 14 days using a microscope FSX100 
(Olympus Life Science, Tokyo, Japan). Then tumoroid size was 
measured using Image J.  
3. 10. Palm fluorescent cells 
The lentiviral reporter constructs of CSCW-palmitoylation 
signal-tandem dimer Tomato (palmT) and CSCW-palmitoylation 
signal-EGFP (palmG) were kindly gifted from Dr. Charles P. Lai (Lai 
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et al. 2015). For virus production, HEK293T cells at 70-80% 
confluence were transfected with PalmT or PalmG constructs, 
psPAX2 packaging plasmid, and pMD2.G envelope plasmid using 
PEI max (Polysciences).  
LuM1 or MMP3-KO cells were infected by using the spinfection 
method with the viral solution. Infected/transduced stable cells were 
selected using puromycin. Isolation of single clones was carried out 
by limiting dilution method. We established palmtdTomato-expressed 
LuM1 cells (designated LuM1/palmT), palmGFP-expressed LuM1 
cells (designated LuM1/palmG), palmGFP-expressed MMP3-KO 
cells (designated MMP3-KO/palmT), and palmGFP-expressed 
MMP3-KO cells (designated MMP3-KO/palmG).To confirm 
fluorescent labeling, the palm fluorescent cells were seeded on a type 
I collagen-coated coverslip in a 24-well plate at a density of 1 × 104 
cells/well in a serum-containing culture media and cultured for 48 h. 
3.11. EVs exchange assay 
Two different colored fluorescent cells (LuM1/palmG and 
LuM1/palmT cells) were used as donor cells or recipient cells with 
each other in the 2D culture system. The donor cells were seeded at 1 
× 106 cells in a 60 cm dish and cultured overnight in a serum-
containing culture media. The grown cells of 70-80% confluence 
were washed twice with PBS, then the culture media was replaced 
with a serum-free medium and cultured for a further 2 days. The 
culture supernatant was collected and centrifuged at 2,000 × g for 15 
min at 4°C to remove detached cells and the supernatants were diluted 
in a ratio 1:1 with a fresh culture medium and used as CM. Recipient 
cells were seeded on a type I collagen-coated coverslip inserted in a 
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24-well plate at a density of 1 × 104 cells/well and cultured for 24 h in 
a serum-containing culture media. The recipient cells were treated by 
donor cells-derived CM for 48 h. For coculturing, recipient MMP3-
KO cells were seeded on coverslips. LuM1-donor cells (1 × 104 
cells/well) were seeded on a culture insert with a 0.45-μm pore 
(Greiner, Kremsmunster, Austria) in a 24 well plate. The insert with 
donor cells was placed on the well containing the recipient cells and 
cocultured for 48 h.  
3.12. 2D confocal laser-scanning microscopy  
Cells were fixed in 4% paraformaldehyde (PFA) for 10 min at 
RT and permeabilized with 0.5% Tween-20 for 10 min. For blocking 
the non-specific reaction of primary antibodies, cells were blocked in 
10% normal goat serum solution (Dako, Tokyo, Japan) for 30 min, 
then incubated overnight at 4℃ with rabbit anti-MMP3 antibody 
(EP1186Y, ab52915, Abcam, Cambridge, UK) or rabbit anti-CD9 
antibody (EPR2949, ab92726, Abcam, Cambridge, UK), for 
overnight at 4˚C and subsequently with a secondary antibody, goat 
anti-rabbit IgG Alexa Fluor 488 (A-11034, Thermo Fisher, Waltham, 
MA, USA) for 1 h at RT.  
As a negative control, the same protocol was performed without 
primary antibody staining. Washes after antibody reactions were done 
with PBS, three times for 3 min each, on a shaker at RT. The mounting 
and DNA staining was performed by using Immunoselect Antifading 
Mounting Medium DAPI (SCR-038448, Dianova, Germany). 
Fluorescent images were taken using a confocal laser scanning 
microscopy LSM780 (Carl Zeiss, Oberkochen, Germany) at Central 
Research Laboratory, Okayama University Medical School. 
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3.13. Immunofluorescence of tumoroids 
For tumoroid formation, cells were cultured for 6 days at a 
density of 3.0 x 105/3 mL mTeSR1 in a well of a 6-well ULA plate. 
Then tumoroids were treated with PBS, the 3D-tumoroid LuM1-EVs 
at a final concentration of 5 μg/mL or the 3D-tumoroid LuM1-CM 
(diluted 1:1 with fresh mTeSR1) for 24 h. Then the plate was 
centrifuged at 1,800 × g for 1 h at 4˚C to increase the internalization 
of EVs into the tumoroids (Lai et al. 2015). Tumoroids were washed 
with PBS and fixed in 4% PFA for 10 min.  
Tumoroids were additionally washed with PBS for 5 min 3 times 
and embedded in paraffin. Tumoroids sections (5 µm thickness) were 
deparaffinized and hydrated through xylenes and graded alcohol 
series. Antigen retrieval was performed by heating the specimens in 
Tris/EDTA buffer, pH 9.0 (Dako target retrieval solution 
S2367, DAKO, Carpenteria, CA) using a microwave for 3 min for 
CD9 or by autoclaving in 0.01M citrate buffer pH 6.0 (sodium citrate 
dihydrate, citric acid; Sigma Aldrich, USA) in a pressure cooker for 
8 min for MMP3 and Ki-67.  
Sections were treated with blocking solution (Dako) for 30 min 
at RT, then incubated with primary antibodies; rabbit anti-CD9 
(EPR2949, ab92726, Abcam, Cambridge, UK), rabbit anti-MMP3 
(EP1186Y, ab52915, Abcam, Cambridge, UK), or rat anti-Ki-67 
antibody (TEC-3, M7249, Dako); individually at 4°C overnight. 
Then, sections were subsequently stained with a secondary antibody 
goat anti-rabbit IgG, Alexa Fluor 488 (A-11034, Thermo Fisher, 
Waltham, MA, USA) for 1 h at RT. Then samples were 
counterstained with 1 mg/mL of DAPI (Dojindo Laboratories, 
Kumamoto, Japan). Fluorescent images were taken using a confocal 
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laser scanning microscopy LSM780 (Carl Zeiss, Oberkochen, 
Germany) at Central Research Laboratory, Okayama University 
Medical School.  
For IHC staining of Ki67, a biotinylated secondary antibody was 
applied for 30 min (Vector Lab, Burlingame, CA) and the color was 
developed with 3, 3’-diaminobenzidine (DAB) (Histofine DAB 
substrate; Nichirei, Tokyo, Japan). Then, samples were 
counterstained with Myer’s hematoxylin and images were taken using 
an optical microscope BX53 (Olympus).  
To calculate the Ki-67 labeling index (%), we counted 
approximately 100 Ki67-positive cells were counted in random five 
fields under the 40× objective. Areas with severe necrosis were 
avoided. The Ki-67 labeling index (%) was calculated by dividing the 
total Ki-67 positive cells by the total numbers of cells multiplied by 
100. The total tumoroid areas, as well as the area of necrotic regions, 
were measured using Image J. The percentage of necrosis was 
calculated by dividing the total necrotic area by the total tumoroid 
area. 
3.14. Hematoxylin and eosin staining 
For tumoroid formation, LuM1 or MMP3-KO cells were cultured 
for 8 days on 6 well ULA plates at a density of 3.0 x 105/3 mL 
mTeSR1/well. Then tumoroids were washed with PBS, fixed in 4% 
PFA for 10 min, and embedded in paraffin. Tumoroids sections (5 µm 
thickness) were deparaffinized in a series of xylene for 15 min, 
rehydrated in graded ethanol solutions, and washed well in distilled 
water. Then sections were incubated in Harris hematoxylin solution 
for 10 min and rinsed in tap water until the water was colorless. 
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Finally, after sequential treatment with hydrogen chloride and 80% 
ethanol solution, sections were incubated in eosin for 7 min.  
3.15. Tracing EV-uptake in vitro  
Ten micrograms of tumoroid-derived EVs were incubated with 0.25 
μM BODIPY TR Ceramide (Thermo Fisher, Waltham, MA, USA) for 
20 min at 37°C. Excessive BODIPY TR Ceramide was removed with 
Exosome Spin Columns (MW 3000) (Thermo Fisher, Waltham, MA, 
USA) (Namba et al. 2018). Cells were seeded at a concentration of 
5.0 x 103 cells/200 μL mTeSR1 in a well of 96-well NCP. The next 
day, EVs were added at a final concentration of 5 μg/mL. The EVs-
uptake was monitored over 24 h using the ArrayScan High Content 
Screening (HCS) system (Thermo Fisher, Waltham, MA, USA). The 
fluorescence intensity of each cell was determined using a filter set 
(485/594) for (GFP/ BODIPY TR). The average fluorescence 
intensity of the PBS treatment group at time point 0 h was evaluated 
as background and subtracted from raw values. 
3.16. Statistical analysis 
Statistical significance was calculated using GraphPad Prism and 
Microsoft Excel. The difference between the sets of data was analyzed 
using ANOVA Tukey’s multiple comparisons test and all data are 
expressed as the mean ± standard deviation unless otherwise 
indicated.  
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4. Results 
4.1. MMP3 knockout reduces the release of CD9 and CD63 within 
extracellular vesicles  
To explore the role of MMP3 on cellular communication in 
cancer, our research group has generated MMP3-KO cells by the 
CRISPR/Cas9 genome editing system from a rapidly metastatic 
murine cancer cell line LuM1 with a parental cancer cell line Colon26 
(aka CT26) (Okusha et al. 2020). The release of EV proteins from 
MMP3-KO-tumoroids tended to decrease compared to LuM1-
tumoroids (Figure 4A-D). However, there was no statistically 
significant difference in the protein concentration of the whole cell 
lysate (WCL) between LuM1 and MMP3-KO-tumoroids.   
MMP3 was markedly detected in the cellular, non-EV, and EV 
fractions of the LuM1, while the complete loss of MMP3 was 
confirmed in MMP3-knockout LuM1 cells, non-EV (including 
soluble proteins), and EV fractions (Figure 4E, top row; Figure S1A), 
suggesting a successful knockout of the Mmp3 gene.  
Next, I examined CD9 (a category-1 EV marker protein) 
expression pattern. Interestingly, the CD9 content was significantly 
down-regulated in both cellular and EV fractions of the MMP3-null 
cells compared to their counterpart (Figure 4E, second and third rows; 
Figure S1B). Moreover, CD63 was reduced in the EV fraction of the 
MMP3-null cells (Figure 4E, fourth and fifth rows; Figure S1C). 
Recently, we have shown that GAPDH and β-actin were released in 
the EV and non-EV soluble fractions upon membrane-damaging cell 
stress (Eguchi et al. 2020). Therefore, I examined the expression 
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levels of β-actin and GAPDH not only as a loading control but also to 
investigate whether they were released within EVs or non-EV soluble 
proteins. Our results revealed that both β-actin and GAPDH were 
detected in the EVs derived from both cell lines, but not in the non-
EV fractions (Figure 4E, bottom lane; Figure S1D, E; Figure S2A). 
Notably, β-actin levels were considered as a loading control for WCL 
and EV fractions, whereas GAPDH was not (Figure S1D, E). 
Furthermore, the SDS-polyacrylamide gel was stained with 
Coomassie brilliant blue (CBB) after the electrophoretic separation 
(Figure S2B). 
These findings demonstrate that MMP3 controls the secretion of 
CD9/CD63-contained EVs.  
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Figure 4. MMP3 knockout reduces the release of CD9 and 
CD63 within extracellular vesicles. Tumoroids were formed in 
10-cm ultra-low attachment (ULA) plates for 6 days. 
Extracellular vesicle (EV) and non-EV fractions were collected 
from the culture supernatants. (A, B) The total protein 
concentration in the (A) EV and (B) whole cell lysate (WCL) 
fractions of LuM1-tumoroids and MMP3-KO tumoroids. (C) 
Relative EV protein ratio comparing two cell lines. (D) EV 
protein concentration per the WCL proteins. ** p < 0.01; ns, not 
significant. (E) Western blotting showing MMP3, CD9, CD63, 
and β-actin in tumoroids, non-EV, and EV fractions. The 54-kD 
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bands indicate the full-length MMP3, the 47-kD bands represent 
the active form consists of the catalytic, hinge, and PEX domains, 
the 37-kD represents the catalytic domain, and the 25-kD shows 
the PEX domain of MMP3. The expression level of β-actin was 
examined as a loading control as well as to check if it was 
released from cells. The protein amounts loaded from WCL and 
EV fractions were 10 µg per lane, while 5 µg per lane was loaded 
from the non-EV fractions. The experiments were repeated twice. 
For full images of Western blotting, see Figure S1. 
 
4.2. MMP3 knockout impacts physical integrities of extracellular 
vesicles  
Further, I examined the morphology and size of EVs secreted 
from “tumoroids” by transmission electron microscopy (TEM) and 
Zetasizer, respectively. Both LuM1- and MMP3-KO tumoroids 
released two types of EVs small EVs (s-EVs) ranged approximately 
50-200 nm and large EVs (L-EVs) more broadly ranged between 200 
and 1000 nm (Figure 5A, B, Table 1). According to their size, the s-
EVs were supposed to be exosomes, while the L-EVs were supposed 
to be microvesicles. 
Meanwhile, crescent moon-like shaped and broken EVs were 
particularly seen in the MMP3-KO EV fraction released by MMP3-
KO tumoroids (Figure 5A, B). Additionally, I observed large 
aggregates (500-800 nm) of EVs derived from MMP3-KO compared 
to their counterparts (Figure 5C). 
Particle diameter distribution analysis using Zetasizer revealed 
that the size of both s-EVs (peaked at 84 nm) and L-EVs (peaked at 
465 nm) released from MMP3-KO tumoroids were smaller than those 
(peaked at 119 nm and 561 nm, respectively) of LuM1 tumoroids 
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(Figure 5D, E). The small particles detected at 5-10 nm in the LuM1-
EV fraction might be damaged membrane vesicles or lipoprotein 
particles e.g. HDL (5–12 nm) which have similar size ranges as EVs 
(Schumaker 1994).  
These findings demonstrate that MMP3 is important for 
maintaining the physical integrities of EVs, and the loss of MMP3 
resulted in disorganizing the EVs structures.  
Table 1. Comparison of particle size distributions between LuM1-
EVs and MMP3-KO-EVs. 
 
 
 
LuM1-EV MMP3-KO-EV 
Peak Diameter 
(nm) 
Intensity 
(%) 
Width 
(nm) 
Peak Diameter 
(nm) 
Intensity 
(%) 
Width 
(nm) 
1 561.4 48.6 164.9 1 464.9 76.6 155.3 
2 119.3 38.3 31.8 2 83.9 20.2 20.4 
3 8.0 6.8 1.53 3 5374 3.2 326.1 
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Figure 5. MMP3 knockout impacts the physical integrities of 
extracellular vesicles. (A-C) TEM images of EV fractions derived 
from the LuM1 and MMP3-KO tumoroids. at (A) low magnification, 
(B) high magnification, and of (C) aggregated EVs. s-EVs, small 
EVs; L-EVs, large EVs. Scale bars, 200 nm (in low magnification), 
and 100 nm (in high magnification). (D, E) Representative histograms 
showing the particle diameter distributions of EVs derived from (D) 
LuM1 tumoroids and (E) MMP3-KO tumoroids. The experiments 
were repeated twice. 
4.3 Loss of the Mmp3 gene reduces the in vitro tumorigenicity  
Next, I examined the consequences of Mmp3 loss on the in vitro 
tumoroid formation. The LuM1 and MMP3-KO cells were cultured 
in the 3D culture system either under serum-containing or mTeSR1 
stemness-enhancing conditions for 14 days. Larger tumoroids were 
formed in the stemness-enhancing medium compared to smaller 
tumoroids seen in the serum-containing medium (Figure 6A-G).                                   
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Figure 6. The loss of the Mmp3 gene reduces the in vitro 
tumorigenicity. Tumoroids were formed in the NanoCulture Plate 
(NCP)-based 3D culture with a serum-containing or stemness-
enhancing medium. (A) Representative images of the LuM1 and 
MMP3-KO tumoroids. The upper panel shows the experimental 
design. (B–G) Tumoroid size quantification on (B) day 3, (C) day 4, 
(D) day 5, (E) day 6, (F) day 7, and (G) day 14 of the tumoroid growth 
periods. N = 39 (LuM1 serum, MMP3-KO serum), n = 21 (LuM1 
stem, MMP3-KO stem). * p < 0.05, ** p < 0.01, *** p < 0.001, **** 
p < 0.0001; ns, not significant. The alternative graphs of Figure 3F, G 
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with tumoroid plotting larger than 100,000 μm2 are shown in Figure 
S3. The experiments were repeated twice.  
 
A highly significant difference in the tumoroid size between 
LuM1 and MMP3-null cells was observed under the stemness-
enhancing culture conditions from day 3 until day 14 (Figure 6A–G; 
Figure S3). The size of MMP3-null tumoroids was significantly 
smaller compared to LuM1 tumoroids (Figure 6B, G; Figure S3). 
Subsequently, I asked whether MMP3-KO and LuM1 cells were 
able to grow if they reseeded under the 2D culture conditions or not.  
I trypsinized tumoroids and reseeded under the 2D culture condition. 
Both cell types proliferated and reached confluency by day 7. More 
interestingly, LuM1 cells were able to grow into tumoroids even under 
the 2D culture condition, whereas MMP3-null cells were not (Figure 
7). 
These data suggest that the stemness-enhancing medium 
promotes the tumorigenic aggregation of tumor cells, whereas the 
serum-containing medium stimulates the cellular differentiation and 
decreasing the fusion of tumoroids. Besides, these findings indicate 
that loss of MMP3 has a great significance on inhibiting the tumoroid 
formation in vitro.  
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Figure 7. Representative images of re-cultured LuM1 and MMP3-
KO cells in 2D culture. Tumoroids on day 14 were trypsinized and 
re-cultured under the 2D culture condition in serum-containing media. 
Scale bars, 100 µm. The experiment was repeated twice. 
 
4.4. The addition of MMP3-rich EVs accelerated the in vitro 
tumorigenesis of MMP3-KO cells. 
I further investigated whether treating the MMP3-KO tumoroids 
with LuM1-EVs (MMP3-rich) or MMP3-KO-EVs (MMP3-null) 
would foster the in vitro tumorigenesis under the 3D culture system. 
A protocol has been shown that seeding the cells first followed by the 
addition of EVs two days later and centrifuging the plate improves the 
uptake of EVs into cells (Lai et al. 2015). As a pilot study, I examined 
this protocol to see the effect of three different concentrations (1.25, 
2.5, and 5 g/mL) of LuM1-EVs on the growth or cytotoxicity in 
MMP3-KO tumoroids. With this protocol, I found that the addition of 
5 g/mL of EVs significantly promoted the tumoroid growth 
compared to the lower concentrations of EVs (Figure S4). 
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I then found that the addition of LuM1-EVs tended to increase 
the size of tumoroids from the next day of the EVs addition to 12 days 
later, while the addition of MMP3-KO-EVs might not promote the 
tumoroid growth (Figure 8A). The growth of MMP3-KO tumoroids 
following the different treatments was monitored by plotting the 
average tumoroid size over the time following the different treatments 
(Figure 8B). The addition of LuM1-derived EVs fostered the 
tumoroids growth compared to the other two groups. 
 
Figure 8. The addition of MMP3-rich EVs accelerated the in vitro 
tumorigenesis of MMP3-KO cells. MMP3-KO tumoroids were 
treated with PBS, LuM1-EVs, or MMP3-KO-EVs at a final 
concentration of 5 g/mL in the NCP-based 3D culture with the 
stemness-enhancing medium. (A) Experimental scheme (top) and 
representative photomicrographs (bottom) of tumoroid maturation at 
the indicated timepoints. Scale bar, 100 µm. (B) A time plot graph 
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showing the average size of the MMP3-KO tumoroids following the 
different treatments over the indicated timepoints. See the next figure 
for statistical analysis.  
 
Notably, the addition of LuM1-EVs resulted in significant 
increases in the size of tumoroids from the next day of the EVs 
addition to 12 days later, while the addition of MMP3-KO-EVs did 
not have any impact on the tumoroid growth (Figure 9A, B). In 
parallel, the comparison of the top 20 tumoroid sizes in the three 
groups revealed that the addition of LuM1-derived EVs significantly 
potentiated the formation of enlarged tumoroids compared to the other 
treatments with MMP3-KO-EVs or PBS (Figure 9C, D).  
I thus found that that (i) MMP3-high, LuM1-derived EVs 
augmented the tumor growth in vitro, and (ii) the loss of MMP3 in 
EVs diminished the protumorigenic properties of the EVs. 
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Figure 9. Tumoroid size was altered by the addition of LuM1-EVs 
versus MMP3-KO-EVs. (A, B) Tumoroid size quantification of (A) 
all tumoroids and (B) tumoroids smaller than 80000 µm2 at the 
indicated time points of the tumoroid formation. Cell aggregates 
(>500 µm2) were considered to be tumoroids. (B) Tumoroids larger 
than 80000 µm2 were shown on the top of the graph. (C, D) Top 20 
tumoroids size quantification on (C) day 3 and (D) day 14.  * p < 0.05, 
** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant; n = 
54–130 (number of plots). The experiments were repeated twice. 
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4.5. Establishment of fluorescent-labeled LuM1 and MMP3-null 
cells  
It has been shown that EVs were derived from the plasma 
membrane (Colombo, Raposo, and Théry 2014) and could be labeled 
with palmitoylation signal-tagged fluorescent proteins (Lai et al. 
2015). To monitor the tumor EVs-uptake and exchange between cell 
populations, the plasma membrane of the LuM1 and MMP3-KO cells 
were labeled with palmitoylation signal-fused fluorescent reporters, 
namely palmG and palmT, thereby green and red labeled cells were 
established (Figure 10A, B). 
 In this EVs exchange assay, if the red/green recipient cells have 
taken up the green/red-EVs from donor cells, an increase in the 
green/red fluorescence signals should be observed, whereas, in non-
treated cells, no green/red fluorescence signals should be detected. 
Indeed, the green/red fluorescence was markedly detected in the cells 
treated with the CM of green/red cells, indicating that EVs were 
exchanged between the cells (Figure 10C, D).  
Additionally, I confirmed the EVs-mediated molecular transfer 
of MMP3 and CD9 under the 2D culture system by treating MMP3-
KO cells with LuM1-CM or by co-culturing with the MMP3 produced 
by the LuM1 cells in the transwell insert. Interestingly, MMP3 was 
restored and detected in the cytoplasmic and nuclear regions of 
MMP3-KO recipient cells after the addition of LuM1-CM or 
coculturing (Figure 10E).  
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The CD9 expression level was low in the MMP3-KO cells as 
shown in Figure 1. However, CD9 was significantly increased in the 
nuclear and cytoplasmic regions of MMP3-KO recipient cells after 
the addition of LuM1-CM or coculturing (Figure 10F). Mmp3 was 
deleted at the genome level, while Cd9 was not in the MMP3-KO 
cells. Therefore, as data interpretation, there were two possibilities 
including that (i) CD9 was transferred from LuM1-EVs to recipient 
cells and/or (ii) endogenous CD9 was induced in the recipient cells 
after the stimulation with LuM1-EVs. 
Collectively, these data prove the successful labeling and 
exchanging of EVs between cell populations. Next, I confirmed the 
exchange of EVs between the cells. Two different colored fluorescent 
cells LuM1/palmG (green) and LuM1/palmT (red) cells were treated 
with each other conditioned media  
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Figure 10. Establishment of fluorescent-labeled LuM1 and 
MMP3-KO cells. (A, B) Fluorescent labeled (A) LuM1 and (B) 
MMP3-KO cells. The stable cells were established by the transfection 
of expression constructs for palmT (red) and palmG (green) 
fluorescent proteins tagged with the palmitoylation signal. Images 
were taken using confocal laser scanning microscopy (CLSM). Non-
fluorescent LuM1 and MMP3-KO cells were used as negative 
controls. (C, D) Molecular transfer of (C) palmG- and (D) palmT-
labeled EVs from the conditioned medium (CM) of donor cells to 
recipient cells. (C) LuM1/palmT cells were treated with/without the 
CM of LuM1/palmG cells. (D) LuM1/palmG cells were treated 
with/without the CM of LuM1/palmT cells. (E, F) Immunostaining of 
(E) MMP3 and (F) CD9 in recipient MMP3-KO/palmT cells 
stimulated with PBS, LuM1-CM, or coculturing with LuM1 cells in 
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the Transwell system. DNA was stained with DAPI (blue). DIC, 
differential interference contrast. Scale bars, 20 µm. The experiments 
were repeated twice. (CM) collected under the 2D culture condition.  
4.6. Penetration of MMP3-rich EVs into organoids 
The bidirectional EVs-mediated transfer of cargo effectively 
influences the recipient phenotype to promote the development of an 
environment hospitable towards the cancer growth, invasion, and 
metastasis (Maacha et al. 2019). Moreover, the roles of EVs in the 
intercellular communication within the tumor microenvironment is 
increasingly acknowledged. Therefore, I examined whether MMP3 
enriched EVs and CM was transferred and penetrating MMP3-null 
recipient tumoroids by immunohistochemistry. MMP3 was well 
detected on the surface and inside of the recipient tumoroids after the 
addition of LuM1-EVs and LuM1-CM (data not shown) (E.A. Taha 
et al., n.d.).  
Additionally, MMP3-null tumoroids contained more space 
between cells and thus more fragile, while the addition of MMP3-rich, 
LuM1-EV, or –CM promoted the formation of solid tumoroids. To 
examine the molecular transfer and penetration of MMP3 into 
tumoroids, I next stained the recipient tumoroids by 
immunofluorescence (IF). To eliminate non-specific reaction, I 
confirmed the specificity of the anti-MMP3 antibody in the 
LuM1/palmT tumoroids (Figure S5).  
To examine molecular penetration and tissue localization of 
MMP3, I used the CLSM. MMP3 from LuM1-EVs and –CM was 
found to penetrate the MMP3-null tumoroids (Figure 11A). Notably, 
intracellular and intranuclear penetration of MMP3 in the recipient 
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tumoroids was seen after the addition of MMP3-rich, LuM1-EVs 
(Figure 11A, B). MMP3 transferred from EVs and CM were seen as 
speckles in cytoplasm and nuclei in the recipient MMP3-null 
tumoroids (Figure 11B). 
I have found that CD9 was decreased in MMP3-KO cells as 
shown in Figure 1 and Figure 7. Next, I examined whether CD9 could 
be altered in the CD9-low, MMP3-KO recipient tumoroids by adding 
LuM1-EVs or -CM. Indeed, CD9 was well stained in the recipient 
tumoroids, especially the parts close to the surface of tumoroids after 
the addition of the MMP3-rich CM or EVs (Figure 12A). Moreover, 
CD9 and endogenous palmT in the recipient tumoroids became 
abundantly expressed on the cell surface and well co-localized seen 
as honeycomb shape, suggesting that CD9 contributed to cell-cell 
adhesion in the recipient tumoroids (Figure 12B).  
These findings indicate that LuM1-derived EVs and CM 
enhanced the solidity of MMP3-null tumoroids, which were relatively 
fragile. Additionally, MMP3 carried by LuM1-EVs was highly 
penetrative and deeply transferred to the recipient MMP3-null 
tumoroids. The intranuclear transfer of MMP3 and the increase in 
CD9 could contribute to the increased solidity in the MMP3-KO 
tumoroids. 
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Figure 11. The EV-mediated deep transfer of MMP3 into 
tumoroids. MMP3-KO/palmT (red) tumoroids were treated with 
PBS, LuM1-CM, or LuM1-EVs for 24 h in the ULA-based 3D 
culture system. MMP3 (green) was stained by immunofluorescence. 
Nuclei were stained blue with DAPI. Images were taken by CLSM. 
(A) low and (B) high magnifications were shown. Scale bars; 100 µm 
(in low magnification images) and 10 µm (in high magnification 
images).   
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Figure 12. Treatment with LuM1-derived EVs and CM 
recovered CD9 in MMP3-null tumoroids. MMP3-KO/palmT (red) 
tumoroids were treated with PBS, LuM1-CM, or LuM1-EVs for 24 
h in the ULA-based 3D culture system. CD9 (green) was stained by 
immunofluorescence.  Nuclei were stained blue with DAPI. Images 
were taken by CLSM. (A) low and (B) high magnifications were 
shown. Scale bars; 100 µm (in low magnification images) and 10 µm 
(in high magnification images).  
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4.7. The knockout of the Mmp3 gene significantly decreased the 
transmissive potential of tumoroid-derived EVs 
We have developed a method to examine the EV transfer to 
tumoroids by labeling EVs with red-fluorescent sphingolipids 
(Namba et al. 2018). In the present study, I monitored whether LuM1 
tumoroid-derived or MMP3-KO tumoroid-derived heterogenous EVs 
(shown in Figure 4) were differently transferred to the MMP3-null 
tumoroids over 24 h.  
I found that the MMP3-null tumoroids rapidly internalized the 
MMP3-rich, LuM1-EVs at a highly significant rate compared to the 
MMP3-null EV from 4 h to 24 h post-EVs addition (Figure 13A, B). 
Furthermore, the EVs uptake by tumoroids was increased in a time-
dependent manner for 24 h (Figure 13B).  
To sum up, these findings indicate that MMP3-rich, LuM1 
tumoroid-derived EVs were highly transmissive and associated with 
tumoroids, while the loss of MMP3 in tumoroid-EVs reduced the 
transmissive and binding properties. These data also support our 
hypothesis that both endogenous and exogenous MMP3 play key 
roles in promoting the tumorigenesis, thereby MMP3-rich EVs were 
rapidly taken up by the MMP3-null tumoroids. 
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Figure 13. The Knockout of the MMP3 significantly decreased 
the transmissive potential of tumoroid-derived EVs. EVs were 
collected after 6 days from the culture supernatants of tumoroids that 
formed in ULA plates. EVs were fluorescently labeled with BODIPY 
TR Ceramide (red). The labeled EVs or PBS were added to the 
MMP3-KO/palmG (green) tumoroids at a concentration of 5 μg/mL 
in the NCP-based 3D culture with the stemness-enhancing medium. 
The uptake of EVs was monitored over 24 h using the high contents 
screening (HCS) system. (A) Time-course imaging of EV uptake 
(red) by MMP3-KO/palmG tumoroids (green) for 24 h. Scale bar, 
100 µm. (B) Red fluorescence intensities of transmitted EVs in 
MMP3-KO/palmG tumoroids. The average fluorescence intensity of 
the PBS treatment group at time point 0 h was evaluated as 
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background and subtracted from raw values. n=3, *P<0.05, 
**P<0.01, and #P<0.001 (LuM1-EVs versus MMP3-KO-EVs). 
 
4.8. MMP3-rich EVs and CM rescue the cell proliferation of 
MMP3-KO tumoroids 
In the course of the present study, I compared the morphological 
characteristics of the LuM1 tumoroids versus MMP3-KO tumoroids 
by histological (H&E) staining.  Five necrotic areas were observed in 
the MMP3-KO tumoroid, whereas only one small necrotic area was 
found in the LuM1 tumoroid (Figure 14A, B). The development of 
necrotic areas in the MMP3-KO tumoroid was at a higher percentage 
compared to the LuM1 tumoroid (15% versus 1% of the total area, 
respectively) (Figure 14A-C). The summed total and the percentage 
of necrotic areas were larger in the MMP3-KO tumoroids compared 
to their counterpart (Table 2).  
 
Table 2. Necrotic areas in the LuM1 tumoroid versus MMP3-KO 
tumoroid 
  LuM1 MMP3-KO 
Total tumoroid area (m2) 331701 64148 
Number of necrotic areas 1 5 
       Sum of necrotic areas 4807 9351 
Necrosis % 1 15 
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Figure 14. MMP3-knockout resulted in necrotic cell death in 
tumoroids. Tumoroids were cultured in the ULA-based 3D culture 
system with a stemness-enhancing medium for 8 days. (A, B) 
Hematoxylin and eosin (H&E) staining of (A) LuM1- and (B) MMP3-
KO tumoroids. Necrotic areas were enclosed with black color, while 
the total tumoroids area was enclosed with yellow color. Scale bars, 
50 µm. (C) The percentage of the necrotic areas in both tumoroids. 
 
Additionally, there was a significant reduction in the Ki-67 
expression, a marker of cell proliferation, in the MMP3-KO cells 
compared to their counterparts (Figure 15A, B). Following the 
addition of MMP3-rich CM and EVs, the recipient MMP3-KO 
tumoroid displayed a highly proliferative phenotype as judged by the 
highly significant increase in Ki-67 expression index (Figure 15A, B). 
These findings prove that MMP3 plays a crucial role in promoting 
cell proliferation in tumoroids and delaying the necrotic process. 
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Figure 15. MMP3 enriched-EVs and CM rescue the proliferation 
of MMP3-KO tumoroids. LuM1-tumoroids or MMP3-KO 
tumoroids were treated with PBS, LuM1-CM, or LuM1-EVs for 24 h, 
and then Ki-67 was immunostained. (A) Ki-67 immunostaining 
(brown) in the LuM1 and MMP3-KO tumoroids. Scale bars, 100 µm 
(in low magnification images), and 10 µm (in high magnification 
images). (B) Ki-67 labeling index (%).  n = 6, ** p < 0.01, *** p < 
0.001; ns, not significant. Experiments were repeated twice. 
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5. Discussion 
5.1. Summary 
MMP3 is a proteolytic enzyme, as well as a transcriptional factor 
that plays a crucial role in tumor progression (Eguchi et al. 2008; 
Okusha et al. 2018; 2020) However, the roles of MMP3 within EVs 
had not unveiled before our study. We recently generated MMP3-KO 
cells by CRISPR/Cas9 system (Okusha et al. 2020) and have analyzed 
their properties in EVs and tumorigenesis.  
In the current study, I found that MMP3 was abundantly detected 
in the high-metastatic cancer cells, their non-EV fluids, and EVs, 
although not in/from MMP3-KO cells. Thus, I newly explored (i) the 
oncogenic role of MMP3 on the in vitro tumoroid formation and on 
their EVs integrity under the 3D culture system, (ii) the tumorigenic 
potential of MMP3-rich versus MMP3-null EVs, and (iii) the EVs-
mediated molecular transfer of MMP3 into the MMP3-KO tumoroids 
under the 3D culture system (Figure. 16).  
5.2. Potential mechanism of how MMP3 promotes tumorigenesis  
Our study indicates that MMP3 contained in EVs promotes 
primary tumorigenesis and metastasis also called secondary 
tumorigenesis. Several studies have reported that several MMP family 
members were packaged in EVs from body fluids or various types of 
cell lines (Dolo et al. 1999; Taraboletti et al. 2002; Belhocine et al. 
2010; Shimoda and Khokha 2013; Reiner et al. 2017; Okusha et al. 
2018). Our current results are consistent with recent data that LuM1-  
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 Figure. 16  Graphical abstracts summarizing the role of MMP3 
on tumorigenesis in vitro.  (A) Illustrating the net results in the 
presence of MMP3  (B) absence of MMP3 protein. 
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EVs (defined as oncosomes) enriched with MMP3 were highly 
transmissive and protumorigenic in vitro and in vivo (Okusha et al. 
2020). MMP3 is one of the epithelial-to-mesenchymal transition 
(EMT) markers in cancer metastasis (Radisky and Radisky 2010), and 
it is well known that MMP3 makes cancer cells detached from solid 
mass and transferred to a distant region of the body (Okusha et al. 
2018). In the current study, I focused on the roles of MMP3 in EVs of 
cancer cell lines for evaluating its tumorigenic potential. 
 As a potential mechanism of the tumorigenesis, MMP3 in EVs 
can penetrate to recipient cells resulting in inducing transformation 
(normal to cancer cells). We have shown that MMP3 could penetrate 
cell nuclei and transactivate connective tissue growth factor gene 
[CTGF aka cell communication network factor 2 (CCN2)] by 
interacting with DNA and heterochromatin proteins (HP1/CBXs) 
(Eguchi et al. 2008; Okusha et al. 2018). Moreover, we recently 
showed that MMP3 contained within EVs penetrate recipient cells 
and their nuclei (Okusha et al. 2020).  
MMP3-rich EVs were able to transactivate the CCN2 gene 
promoter, while knockout of MMP3 from the EVs abolished this 
transactivating effect. The induction of CCN2 could be a key 
mechanism by which MMP3 induces transformation and tumor 
progression, as the stromal expression of CTGF promotes 
angiogenesis and prostate cancer tumorigenesis (F. Yang et al. 2005). 
Moreover, CCN2 modulates cell cycle progression through the 
upregulation of cyclin A (Kothapalli and Grotendorst 2000). Besides, 
CTGF is associated with oncogenic activities in glioblastoma by 
inducing the expression of the antiapoptotic proteins, Bcl-xl, 
surviving, and Flip (Yin et al. 2010). Thus, the protumorigenic effect 
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of MMP3 could be partially mediated by the induction of this multi-
functional factor, CTGF. 
Intranuclear MMP3 can also trans-activate HSP genes encoding 
cytoprotective factors, in collaboration with HP1/CBXs  (Eguchi et 
al. 2017). Thus, intranuclearly translocated MMP3 could regulate 
broader intranuclear proteins and genes, some of which could be 
involved in cellular transformation such as EMT. Our current data 
indicated that MMP3 might also regulate CD9 and CD63 at 
transcriptional or post-transcriptional levels. The transactivating role 
of MMP3-EVs on the CCN2 gene was strictly mediated by a cis-
element called TRENDIC (Okusha et al. 2020). Therefore, it would 
be important to verify which gene promoters contain TRENDIC-like 
motifs that are directly bound by MMP3. Some target genes regulated 
by MMP3 may involve cellular transformation. 
Moreover, intranuclearly penetrating MMP3 could initiate 
cellular transformation by cleaving particular intranuclear proteins. It 
has become clear that the function of MMPs was not only restricted 
to degrade or inactivate matrix proteins and that proteolysis by MMPs 
can modulate or even increase functions of substrate proteins (Nelson 
et al. 2000).  
Simultaneously, EV-associated MMP3 could activate 
extracellular transforming signals such as TGFβ by cleaving their pro-
forms or inhibitory factors. Activities of many proteins are positively 
regulated by MMP proteolysis including CCN2/CTGF (Hashimoto et 
al. 2002; Kaasbøll et al. 2018; Okusha et al. 2020), insulin growth 
factor binding proteins (IGFBPs) heparin-binding epidermal growth 
factor (HB-EGF) (Suzuki et al. 1997), fibroblast growth factor 
receptor 1 (FGFR1) (Levi et al. 1996), interleukin-1beta (IL-1β) (Ito 
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et al. 1996), and tumor necrosis factor-alpha (TNF-α) (Haro et al. 
2000). Such proteins activated by MMPs strengthen our in vitro 
findings that MMP3 can foster tumor development by modulating the 
activities of many signaling pathways and their receptors. Our 
research group is currently investigating such mechanisms of 
transformation induced by MMP3.  
5.3. Potential role of MMP3 in cryoprotection 
Our data suggest that MMP3 contained in EVs plays a 
cytoprotective role in tumors. Knockout of MMP3 markedly 
increased necrotic area in tumors thereby inhibited tumor growth. The 
addition of MMP3-rich EVs rescued tumor growth by increasing 
proliferating cells. Therefore, it is conceivable that MMP3 has 
cytoprotective and stimulates cell proliferation in tumors. Such 
cytoprotective and proliferative roles of MMP3 could be mediated by 
downstream factors such as HSPs and CTGF/CCN2 (Eguchi et al. 
2008; 2017). We showed that intranuclear MMP3 can trans-activate 
HSP genes encoding cytoprotective factors, in collaboration with 
HP1/CBXs (Eguchi et al. 2017). Besides, CCN2 modulates cell cycle 
progression through the upregulation of cyclin A (Kothapalli and 
Grotendorst 2000).  
Indeed, the MMP3-null tumoroid size was significantly smaller 
than their parental counterpart. Besides, the necrotic onset was 
occurring at a higher rate in the MMP3-null tumoroid compared to the 
LuM1 tumoroids. Necrosis is an accidental death of cells that are 
induced in response to extreme physiological conditions, such as 
hypoxia, toxin exposure, ischemia, reactive oxygen species exposure, 
nutrient deprivation, and extreme temperature changes (Walker et al. 
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1988; Nicotera, Leist, and Manzo 1999). Indeed, inside 
tumoroids/tumors are hypoxic and deprived of nutrients (Eguchi et al. 
2018; Namba et al. 2018; Yoshida et al. 2019), although some 
cytoprotective factors could protect cells against necrotic cell death. 
Morphologically, necrotic cell death is characterized by swelling of 
the cellular organelles, a process of oncosis (also called ischemic cell 
death), and early plasma membrane rupture leading to loss of 
intracellular content (Parhamifar et al. 2014). The cell death observed 
in tumoroids in the current study fit the morphological criteria of 
necrosis.  
Our data also indicated that MMP3 is a regulator for the physical 
and biological characteristics of EVs. Tetraspanins CD9 and CD63, 
category-1 EV markers, were downregulated in MMP3-null EVs 
compared to their counterparts (Figure 1E, F), suggesting that MMP3-
knockout reduced the endogenous production or stability and 
subsequent release of CD9/CD63-contained EVs. It has been known 
that tetraspanins, CD326/EpCAM (these are category-1 EV markers), 
and the tight junction protein claudin-7 partners associate with each 
other for cell-cell adhesion and apoptosis resistance (Naour 2008). 
Moreover, tetraspanin interaction with another tetraspanin and 
integrins often depended on palmitoylation (Charrin et al. 2002; X. 
Yang et al. 2004). Therefore, MMP3-KO-triggered loss of CD9 and 
CD63 could reduce the cell-cell and EV-cell adhesions required for 
tumoroid integrity.  
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5.4. Release of L-EVs and s-EVs from 3D tumoroids 
The morphological visualization of EVs showed abnormal 
disorganized shapes of EVs such as, crescent moon-like and broken 
EVs that were associated with the Mmp3 loss. These data indicated 
that MMP3 is necessary for maintaining the stability of structural 
proteins required for the integrity of EVs.  
Besides, we distinguished two subpopulations of 3D tumoroid-
derived EVs, namely s-EVs (50-200 nm) and L-EVs (200-1000 nm). 
It is worth noting that, under the 2D culture system both LuM1 and 
MMP3-KO cells secreted homogeneous intact s-EVs (50-300 nm 
diameter) (Okusha et al. 2020). This inconsistency is due to our 
current study was performed under the 3D culture system which is 
completely different from the 2D culture system. Thus, intra-
tumoral hypoxia developed under the 3D culture model may be 
stimulated the production of L-EVs. The release of both s-EVs and L-
EVs might be a signature characteristic of the 3D tumoroids, a model 
resembling of tumors in vivo.  
It has been reported that adipocytes secreted L-EVs containing 
cytoskeletal proteins and molecular chaperones, whereas s-EVs were 
shown to contain ECM proteins (Durcin et al. 2017). Moreover, the 
proteomic analysis of s- and L-EVs derived from a colorectal cancer 
cell line revealed that s-EVs were enriched with proteins associated 
with cell-matrix adhesion and cell-cell junctions (Jimenez et al. 2019). 
Similarly, s-EVs from fibrosarcoma cells showed similar enrichment 
for adhesion proteins (Jimenez et al. 2019). Likewise, one of our 
recent studies has demonstrated that the prostate cancer (PC-3) cells 
release two types of vesicles, s-EVs (30-200 nm) under a non-heated 
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condition, L-EVs (200-500 nm) and membrane-damaged EVs which 
were associated with HSP90α expression (Eguchi et al. 2020). 
Notably, both membrane-damaged EVs and L-EVs were co-released 
upon the heat shock stress, suggesting that vesicular membranes were 
damaged by the stress (Eguchi et al. 2020). Thus, the two different 
EVs populations may play distinct biological roles in the recipient 
cells. Our research group is currently challenging to separate the s- 
and L-EVs from the tumoroids and distinguish their properties.  
5.5. Fluorescent labeling of EVs 
 To monitor the transmission and uptake of EVs between cells, I 
used two systems (i) PalmGFP and PalmtdTomato (Figure 10) or (ii) 
BODIPY TR ceramide labeled EVs (Figure 13). By utilizing the first 
system, I detected a robust fluorescent signal of donor-derived EVs in 
recipient cells, indicating that the bidirectional exchange of EVs 
between the cells.  
Of note, PalmGFP and PalmtdTomato EV labeling strategy were 
designed to visualize and track multiple EV subtypes. Furthermore, 
by using these reporters, 0.22- and 0.8-μm sized EV populations, as 
well as sucrose density gradient with EV-marker proteins (such as 
Alix) were observed (Lai et al. 2015). Through the second EVs 
monitoring system, I tracked the uptake rate of MMP3-rich versus 
MMP3-null EVs for 24 h. An increase in BODIPY TR ceramide/EVs 
signal was noticed as early as 3 h post-EVs exposure period, and the 
increase continued until reached the saturation level after 24 h (Figure 
13).  
Thus, both fluorescent-EV monitoring systems were useful for 
monitoring the EV exchange. It has been shown that uptake of EVs 
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occurred via multiple routes, such as the direct fusion between EVs 
and the plasma membrane (Parolini et al. 2009), as well as EV 
internalization through lipid raft-, clathrin- and caveolae-dependent 
endocytosis, macropinocytosis, and phagocytosis (Morelli et al. 2004; 
Feng et al. 2010; Escrevente et al. 2011; Fitzner et al. 2011; Nanbo et 
al. 2013; Svensson et al. 2013). However, it is unclear which 
mechanism(s) is employed in different cell types under various 
conditions.  
5.6. Inter MMPs regulation 
Besides, EV-derived MMPs could promote proteolysis in 
recipient cells leading to tumor progression. Wang et al. indicated that 
EVs derived from adipocytes promoted lung cancer metastasis via 
transferring MMP3 that resulted in increasing the MMP9 activity in 
lung cancer cells (Wang et al. 2017). It has been shown that one MMP 
can activate another MMP including other members of MMPs. 
Therefore, the high expression of active MMP3 and/or MMP9 could 
activate other MMPs.  
Indeed, I have shown that both MMP3 and MMP9 were 
expressed at high levels in LuM1 cells and proved their important role 
in tumor progression (Okusha et al. 2018). Nevertheless, the loss of 
MMP3 was crucial to reduce tumor and EV development. Our data 
indicate that exogenous MMP3 can be positioned at a higher level in 
the protease cascade that promotes tumor progression in the recipient 
cells. 
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6. Conclusion 
Our study demonstrated that the loss-of-function of MMP3 
significantly decreased the 3D-tumoroids formation in vitro, reduced 
tetraspanins (CD9 and CD63) in EVs and, resulted in destabilizing the 
EVs structural integrity. Moreover, I proved the successful labeling, 
exchanging of EVs between cells, and established a bidirectional EV 
transfer assay system. I confirmed the EVs-mediated molecular 
transfer of MMP3 into the MMP3-KO tumoroids under the 3D culture 
system. Also, I found that the addition of MMP3-enriched EVs 
(defined as oncosomes) fostered the tumorigenicity and increased the 
proliferation of MMP3-null cells. Thus MMP3-enriched oncosomes 
are highly transmissive and protumorigenic. 
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7. Supplementary Figures 
 
 
 
 
Figure S1. Full images of Western blotting of (A) MMP3, (B) CD9, 
(C) CD63, (D) β-actin, and (E) GAPDH, supporting Figure 1. Images 
from long and short exposure times are shown. The protein amount 
loaded from WCL and EV fractions was 10 µg per lane, while 5 µg 
per lane was loaded from the non-EV fractions.   
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Figure S2. Images of (A) GAPDH Western blotting and (B) CBB 
staining of the SDS-PAGE. The amount of protein sample loaded for 
the CBB staining was 1µg per each lane. 
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Figure S3. Column scatters plotting of the size of LuM1 
tumoroids versus MMP3-KO tumoroids cultured for (A) 7 days 
or (B) 14 days in serum-containing or stemness media, 
supporting Figure 3.  Data were represented as mean ± SD, n = 
3, ** p < 0.01, **** p < 0.0001; ns, not significant. 
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Figure S4. Evaluation of the effect of three different 
concentrations of LuM1-EVs on the MMP3-KO tumoroids 
growth. MMP3-KO tumoroids were treated with LuM1-EVs at a 
concentration of 1.25, 2.5, 5 µg/mL in the NCP-based 3D culture with 
the stemness-enhancing medium. Scale bar, 100 µm. (B, C) Tumoroid 
size quantification on (B) day 3 and (C) day 5 of the tumoroid 
formation periods. Data were represented as mean ± SD, n = 3, *** p 
< 0.001; ns, not significant. 
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Figure S5. The specificity of the MMP3 antibody. (A, B) MMP3 
expression (green) in (A) positive (B) and negative controls; 
LuM1/palmT tumoroids were stained with or without the MMP3 
antibody, then stained with the secondary AF488 antibody. Nuclei 
were stained blue with DAPI. Images were taken by CLSM. w/o Ab; 
without antibody Scale bar 100 µm. 
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